Dr. Dorothy Hatsukami, Forster Family Professor in Cancer Prevention and Professor of Psychiatry at the University of Minnesota Tobacco Use Research Center, will participate in a roundtable discussion and present "Vaccination as an Aid to Smoking Cessation: Initial Results from a Phase IIb Trial of NicVAX(R) (Nicotine Conjugate Vaccine)" at the conference at 12:15 p.m. local time on Friday, June 1, 2007. Dr. Hatsukami will discuss the advantages of a vaccine approach to smoking cessation and will outline key conclusions of the recently announced Phase IIb trial: -- NicVAX is well-tolerated -- The NicVAX trial demonstrated a relationship between high antibody titers and continued smoking abstinence at six months -- NicVAX proof of concept was achieved in the trial Per the Phacilitate conference guidelines, Dr. Hatsukami's presentation will be available on the Nabi website after market close on June 1, 2007. About the NicVAX Phase IIb Trial The Phase IIb study is an ongoing double-blind, placebo-controlled and dose-ranging study comprised of 301 patients and is designed to establish proof of concept and the optimal dose for the Phase III program. This study was designed in collaboration with the U.S. Food and Drug Administration and other global regulatory agencies and incorporates the most current clinical trial standards and prevailing protocol design for smoking cessation studies. The trial's primary endpoint is the rate of carbon monoxide (CO)- confirmed, continuous abstinence from smoking during weeks 19-26 after first vaccination. Full evaluation of abstinence at the six-month primary endpoint will include reported cigarette consumption, chemical markers of nicotine in the bloodstream, and behavioral assessment. Secondary endpoints include the abstinence rate at 12 months, total cigarette consumption, antibody levels, safety and nicotine dependency. About NicVAX and NIDA In September 2005, the company announced that it received a $4.1 million grant from the National Institute on Drug Abuse (NIDA) which is part of the National Institutes of Health. NIDA has also funded, in part, the costs for toxicology testing and earlier clinical trials in the U.S. and contributed scientific and clinical expertise to the program overall. About Nabi Biopharmaceuticals Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has one product on the market today: Nabi-HB(R) [Hepatitis B Immune Globulin (Human)]. Nabi Biopharmaceuticals is focused on developing products that address unmet medical needs and offer commercial opportunities in our core business areas: Hepatitis and transplant, Gram- positive bacterial infections and nicotine addiction. The company recently announced that it intends to form two strategic business units: Nabi Biologics and Nabi Pharmaceuticals. Nabi Biologics will have responsibility for the company's protein and immunological products and development pipeline, including Nabi-HB. Nabi Pharmaceuticals will have responsibility for the NicVAX(R) (Nicotine Conjugate Vaccine) and StaphVAX(R)-Pentavalent (Staphylococcal Polysaccharide Conjugate and Toxoid Vaccine) development programs, as well as for the continuing milestone-related clinical development obligations following the sale of PhosLo(R) (calcium acetate). For a complete list of pipeline products, please go to:

<< Prev	CIGoutlet.NET News Home	Next >>